BioPharma Resources

Drug Trial Radar · NCT07291284

Efficacy and Safety of LP-003 Injection in Patients With Moderate to Severe Seasonal Allergic Rhinitis

A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Moderate to Severe Seasonal Allergic Rhinitis Inadequately Controlled by Standard-of-care

Last checked: Nov 19, 2026Latest source record: Dec 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 546 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

546

Actual

Start

Aug 1, 2024

Primary completion

Mar 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Longbio PharmaIndustry
Sponsor type
Industry
First posted
Dec 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy and safety of LP-003 injection in patients with moderate to severe seasonal allergic rhinitis inadequately controlled by standard-of-care.

Conditions

  • Seasonal Allergic Rhinitis

Interventions

  • LP-003Biological

    Participants were administered LP-003 via subcutaneous injection every 4 weeks.

  • PlaceboBiological

    Participants were administered Placebo via subcutaneous injection every 4 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean daily reflective total nasal symptom score (rTNSS) during the pollen peak period (PPP)Time frame: Up to 4 Months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Shijitan Hospital, Capital Medical University (the formerly Beijing Railway General Hospital)

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.